Basel, Switzerland / Leiden, The Netherlands (September 25, 2008) -Lonza (Swiss Exchange: LONN) and Crucell N.V. (Euronext, Nasdaq:CRXL; Swiss Exchange: CRX) entered into a co-exclusive manufacturing,sales and distribution agreement related to the PERMEXCIS(TM) cellculture medium developed by Crucell for PER.C6® cells. Under thisagreement, Lonza will manufacture the medium, and in addition willmarket and sell it on a global basis. Financial details of theagreement were not disclosed.

The PERMEXCIS(TM) medium is a chemically defined cell culture mediumthat does not contain human- or animal-derived components.PERMEXCIS(TM) medium was developed for the cultivation of PER.C6®cells and has been designed for use in the large-scale manufacture ofbiopharmaceutical products including vaccines. This novel medium hasproven, in a comparison study performed by Crucell, to provide higherviral vaccine product yields in PER.C6® based manufacturing processesthan some of the current available media for PER.C6® cells on themarket.

"We are pleased to have entered into this agreement with Lonza. Theagreement demonstrates the power and robustness of our PER.C6®technology. Over 60 companies and organizations have already selectedour PER.C6® technology to develop their own products across a widerange of therapeutic areas. We are proud that Lonza will manufacturethe PERMEXCIS(TM) cell culture medium and in addition will market andsell it globally" said Ronald Brus, Crucell's Chief ExecutiveOfficer.

About PER.C6® Technology

Crucell's PER.C6® technology platform has been developed for thelarge-scale manufacture of biopharmaceutical products such asrecombinant proteins including monoclonal antibodies. Compared toconventional production technologies, the strengths of PER.C6®technology lie in its excellent safety profile, scalability andproductivity under serum-free culture conditions.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical,healthcare and life science industries. Its products and servicesspan its customers' needs from research to final product manufacture.Lonza is the global leader in the production and support of activepharmaceutical ingredients both chemically as well asbiotechnologically. Biopharmaceuticals are one of the key growthdrivers of the pharmaceutical and biotechnology industries. Lonza hasstrong capabilities in large and small molecules, peptides, aminoacids and niche bioproducts which play an important role in thedevelopment of novel medicines and healthcare products. Lonza is aleader in cell-based research, endotoxin detection and cell therapymanufacturing. Lonza is also a leading provider of value chemical andbiotech ingredients to the nutrition, hygiene, preservation, agro andpersonal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWXSwiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Furtherinformation can be found at www.lonza.com.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharma company focused on research, development, productionand marketing of vaccines, proteins and antibodies that prevent andtreat primarily infectious diseases. Its vaccines are sold in publicand private markets worldwide. Crucell's core portfolio includes avaccine against hepatitis B, a fully-liquid vaccine against fiveimportant childhood diseases and a virosome-adjuvanted vaccineagainst influenza. Crucell also markets travel vaccines, such as theonly oral anti-typhoid vaccine, an oral cholera vaccine and the onlyaluminum-free hepatitis A vaccine on the market. The Company has abroad development pipeline, with several product candidates based onits unique PER.C6® production technology. The Company licenses itsPER.C6® technology and other technologies to the biopharmaceuticalindustry. Important partners and licensees include DSM Biologics,sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell isheadquartered in Leiden, the Netherlands, with subsidiaries inSwitzerland, Spain, Italy, Sweden, Korea and the US. The Companyemploys over a 1000 people. For more information, please visitwww.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certainimportant factors that may cause actual results to differ materiallyfrom those contained in such forward-looking statements. Forinformation relating to these factors please refer to our Form 20-F,as filed with the U.S. Securities and Exchange Commission on May 7,2008, and the section entitled "Risk Factors". The Company preparesits financial statements under International Financial ReportingStandards (IFRS).

For further information please contact:Crucell N.V.Oya YavuzDirector Corporate Communications & Investor RelationsTel. +31-(0)71-519 7064ir@crucell.comwww.crucell.com

Copyright © Hugin AS 2008. All rights reserved.